Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well vorinostat works in treating women who are
undergoing surgery for newly diagnosed stage I, stage II, or stage III breast cancer.
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving vorinostat before surgery may shrink the tumor so that it can be removed.